Pharmacokinetics and toxicity of idarubicin in the rat

被引:0
|
作者
Kuhlmann, O
Hofmann, S
Weiss, M [1 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, Sect Pharmacokinet, D-06097 Halle Saale, Germany
[2] Univ Halle Wittenberg, Dept Cardiothorac Surg, D-06097 Halle Saale, Germany
关键词
idarubicin; idarubicinol; rat; lung; pharmacokinetics;
D O I
10.1007/BF03226374
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was designed to examine the pharmacokinetics and toxicity of idarubicin (IDA) in rats. In two groups of rats IDA was infused either into the V. iugularis interna or into the A. carotis communis, respectively. The venous plasma concentration of IDA and its primary metabolite idarubicinol (IDOL) were measured up to 48 hours by high - performance liquid chromatography (HPLC) with fluorescence detection. The weights of the rats and the levels of haemoglobin, leukocytes, and thrombocytes were recorded. The plasma concentration - time data were analysed, assuming a biexponential disposition curve, both by the traditional (two - stage) method and by population pharmacokinetic modelling. The basic pharmacokinetic parameters clearance (CL = 27.0 ml min(-1)), mean disposition residence time (MDRT = 519.2 min), and volume of distribution at steady state (V-ss = 12.51) were estimated for IDA. The mean residence time (MRT) of the generated IDOL was 2982.5 min. No significant differences between pre- and postpulmonal injection were found in the pharmacokinetics and pharmacodynamics of IDA. The mean survival time of 13.3 days is attributed to a severe myelosuppression.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [21] EVALUATION OF CARDIAC TOXICITY OF IDARUBICIN (4-DEMETHOXYDAUNORUBICIN)
    VILLANI, F
    GALIMBERTI, M
    COMAZZI, R
    CRIPPA, F
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (01): : 13 - 18
  • [22] PHARMACOKINETICS OF IDARUBICIN AFTER DAILY INTRAVENOUS ADMINISTRATION IN LEUKEMIA PATIENTS
    ROBERT, J
    RIGALHUGUET, F
    HAROUSSEAU, JL
    REIFFERS, J
    HURTELOUP, P
    INVESTIGATIONAL NEW DRUGS, 1987, 5 (01) : 114 - 114
  • [23] Idarubicin containing regimen for HSCT prolongs mucosal toxicity
    Herbers, A. H. E.
    Donnelly, J. P.
    Blijlevens, N. M. A.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S80 - S80
  • [24] DIFFERENT CYTO-TOXICITY AND METABOLISM OF DOXORUBICIN, DAUNORUBICIN, EPIRUBICIN, ESORUBICIN AND IDARUBICIN IN CULTURED HUMAN AND RAT HEPATOCYTES
    LEBOT, MA
    BEGUE, JM
    KERNALEGUEN, D
    ROBERT, J
    RATANASAVANH, D
    AIRIAU, J
    RICHE, C
    GUILLOUZO, A
    BIOCHEMICAL PHARMACOLOGY, 1988, 37 (20) : 3877 - 3887
  • [25] Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit
    M. Looby
    R. Linke
    M. Weiss
    Cancer Chemotherapy and Pharmacology, 1997, 39 : 554 - 556
  • [26] Intracellular pharmacokinetics of idarubicin and idarubicinol in highly resistant acute leukemia cells
    Gieseler, F
    Hoppe, N
    Kunze, T
    Glasmacher, A
    Borleri, G
    Bassan, R
    Barbui, T
    BLOOD, 2003, 102 (11) : 862A - 862A
  • [27] DIFFERENTIAL TOXICITY AND PHARMACOKINETICS OF SODIUM AND TRIS SALTS OF 5-FLUOROURACIL IN THE RAT
    PLUMB, JA
    GARDNER, MLG
    CLINICAL SCIENCE, 1981, 60 (06) : 707 - 710
  • [28] INFLUENCE OF LOVASTATIN ON THE PHARMACOKINETICS, TOXICITY AND IMMUNOLOGICAL RESPONSE OF CYCLOSPORINE IN THE OBESE ZUCKER RAT
    BERENS, KL
    VADIEI, K
    BRUNNER, LJ
    WASAN, KM
    LUKE, DR
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (03) : 197 - 206
  • [29] COMPARISON OF THE INTRACELLULAR PHARMACOKINETICS OF DAUNORUBICIN AND IDARUBICIN IN PATIENTS WITH ACUTE-LEUKEMIA
    TIDEFELT, U
    SUNDMANENGBERG, B
    PAUL, C
    LEUKEMIA RESEARCH, 1994, 18 (04) : 293 - 297
  • [30] TOXICITY AND PHARMACOKINETICS OF THE NONPROTEIN AMINO-ACID L-CANAVANINE IN THE RAT
    THOMAS, DA
    ROSENTHAL, GA
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 91 (03) : 395 - 405